Schizophrenia (SCZ) and bipolar disorder (BP) are the major adult psychotic disorders; uncertainty about their relationship is a central issue in psychiatry. By discovering variants with a high impact on either or both disorders (or on their endophenotypes) we can transform our understanding of their biology. This multisite project, from investigators with a track record of successful collaboration, will leverage exceptional, extensively phenotyped pedigree and population samples and integrate a combination of bioinformatics and experimental genomics approaches to identify such variants and demonstrate their relationship to these diseases. We will proceed through three steps: (1) Detect novel variants by whole genome sequencing (WGS) of discovery samples from ethnically homogenous populations; (2) Prioritize genome regions for further studies of these variants, using bioinformatics and functional genomics analyses; (3) Identify disease related variants through (a) imputation-based association analyses in very large case/control samples from the same populations and (b) validation of associated and predicted-deleterious variants using novel high-throughput functional assays. The WGS discovery sample includes SCZ, BP, and control individuals from Finland (FIN) and the Netherlands (NL). We will analyze their variants using a pipeline already implemented by our group to analyze the completed WGS of BP pedigrees from recently bottlenecked Latin American founder populations. The majority of our WGS samples derive from such founder populations; as we have shown previously this creates a high probability of detecting deleterious variants in these samples. WGS will detect a huge number of variants, most of unknown functional significance. We will thus narrow our focus to regions (coding and non-coding) most likely relevant to SCZ and BP, using two approaches: (1) Bioinformatics to prioritize regions previously implicated in these disorders (e.g. GWAS or CNV loci, or variants highlighted in prior sequencing studies including that of our BP pedigrees) and candidate regulatory regions (through analyses of ENCODE or other reference data); (2) Sequencing-based assessments of transcriptomic and epigenomic variation that we will conduct in two unique samples relevant to our phenotypes: fibroblasts from affected and unaffected members of our BP pedigrees; and neuronal and neuronal progenitor cells from reference individuals. We will then leverage very large, genotyped case/control samples available from the same populations as our discovery samples (or closely related ones) to accurately impute the novel variants from our prioritized regions; this will enable us to identify associations with SCZ, BP, and/or endophenotypes. Finally, in an initial validation study, we will use a novel high-throughput sequence-based reporter assay to evaluate the function of putative regulatory variants highlighted by our bioinformatics pipeline or by our association analyses.

Public Health Relevance

Uncertainty about the genetic relationship between bipolar disorder and schizophrenia has been a major obstacle to understanding the biological underpinnings of these conditions. Through whole genome sequencing of cases and controls, genome-level experimental studies of gene function, and a series of bioinformatic and statistical analyses, this project will elucidate this relationship by identifying genetic variants with a high impact on one or both disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01MH105666-04
Application #
9325572
Study Section
Special Emphasis Panel (ZMH1)
Program Officer
Addington, Anjene M
Project Start
2014-09-23
Project End
2019-07-31
Budget Start
2017-09-07
Budget End
2019-07-31
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Ganna, Andrea; Satterstrom, F Kyle; Zekavat, Seyedeh M et al. (2018) Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. Am J Hum Genet 102:1204-1211
Gormley, Padhraig; Kurki, Mitja I; Hiekkala, Marjo Eveliina et al. (2018) Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families. Neuron 98:743-753.e4
Short, Patrick J; McRae, Jeremy F; Gallone, Giuseppe et al. (2018) De novo mutations in regulatory elements in neurodevelopmental disorders. Nature 555:611-616
Sanders, Stephan J; Neale, Benjamin M; Huang, Hailiang et al. (2017) Whole genome sequencing in psychiatric disorders: the WGSPD consortium. Nat Neurosci 20:1661-1668
Singh, Tarjinder; Walters, James T R; Johnstone, Mandy et al. (2017) The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 49:1167-1173
Ganna, Andrea; Genovese, Giulio; Howrigan, Daniel P et al. (2016) Ultra-rare disruptive and damaging mutations influence educational attainment in the general population. Nat Neurosci 19:1563-1565